BioPorto
2,14 DKK −0,47%HC Andersen Capital saa maksun yhtiöltä BioPorto DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Lue lisääViimeisimmät analyysit
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Viimeisimmät videot
Pörssikalenteri
Changes of number of shares and votes in BioPorto A/S
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
PREMIUM-tili
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
![Bioporto: New EVP and CFO Niels Høy Nielsen](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/73678f7a-c660-4077-b3a9-caf26ac5f05f.png)
Bioporto: New EVP and CFO Niels Høy Nielsen
BioPorto A/S Appoints Chief Financial Officer
![BioPorto share is markedly up as new CEO for US is hired, and management remains confident at event after strong Q1 report](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/73678f7a-c660-4077-b3a9-caf26ac5f05f.png)
BioPorto share is markedly up as new CEO for US is hired, and management remains confident at event after strong Q1 report
First Quarter 2024: Strong growth in US sales of The NGAL Test
Resolutions of Annual Geneal Meeting
Grant of warrants
BioPorto A/S Appoints Chief Legal Officer
New Board Candidate for the upcoming Annual Geneal Meeting
![Bioporto: Wrap up from interview with CEO Peter M. Eriksen](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/73678f7a-c660-4077-b3a9-caf26ac5f05f.png)
Bioporto: Wrap up from interview with CEO Peter M. Eriksen
Notice convening the Annual General Meeting in BioPorto A/S
Correction: BioPorto Announces Annual Results for 2023
BioPorto Announces Annual Results for 2023
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)